All In Biotech

Free tool

FAERS Monitor: Isopto Atropine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208151 or its brand name (Isopto Atropine, Atropine Sulfate). Reports on generic versions are filed under their own applications.

Reports

2,595

Serious

2,182

84% of reports

Hospitalization

978

Death reported

414

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective315
  • off label use214
  • macular degeneration199
  • nausea192
  • pyrexia162
  • diarrhoea150
  • pain138
  • malaise132
  • headache129
  • death124
  • weight decreased120
  • constipation117
  • erythema109
  • anaemia105
  • vomiting105

Reports by year received

View as table
YearReports
200455
200562
200650
200755
200873
200945
201075
201167
201271
201360
201468
201578
2016117
201797
2018125
2019184
2020164
2021152
2022230
2023237
2024236
2025189
2026104

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
macular degenerationSignal199137.3120.026,361
anaemiaSignal1054.53.7281
constipationSignal1174.43.6301
erythemaSignal1094.33.6275
pyrexiaSignal1623.83.3336
weight decreasedSignal1203.52.9213
malaiseSignal1322.42.1113
off label use2142.01.7107
nausea1922.01.794
drug ineffective3151.91.7151
diarrhoea1501.91.663
pain1381.81.552
vomiting1051.81.538
headache1291.71.435
death1241.21.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.